Renal outcomes of both treatment groups. حسب Marwan El-Deyarbi (21688492)

"…Participants in the multifactorial group achieved a significant mean difference in low-density lipoprotein cholesterol levels (mean difference = −0.14, 95% CI: −0.27–0.001, P < 0.03), and significant adjusted mean difference of eGFR levels difference (3.93 mL/min/1.73 m², 95% CI: 1.27–6.58, P < 0.01) at study completion compared to those in the control group. …"

Raw database. حسب Franco Romaní-Romaní (21989788)

"…The mean score across all tests was 9.19 (standard deviation = 2.34). …"

PRISMA flowchart of the included studies. حسب Gaelle Salame (21077899)

"…</p><p>The combined data showed that patients receiving immunotherapy had higher C-peptide levels (Mean Difference (MD) = 1.51; 95% Confidence Interval (CI): [-2.56, 5.58]); however, this difference was not statistically significant (p = 0.42). …"

Characteristics of Included Studies. حسب Gaelle Salame (21077899)

"…</p><p>The combined data showed that patients receiving immunotherapy had higher C-peptide levels (Mean Difference (MD) = 1.51; 95% Confidence Interval (CI): [-2.56, 5.58]); however, this difference was not statistically significant (p = 0.42). …"

Adverse event list. حسب Stefan Halbherr (21353882)

"…No statistically significant improvements were seen in the Montreal Cognitive Assessment (MoCA) (mean decrease −0.73; 95% CI; −2.1, 0.62; <i>p</i> = 0.255), Epworth Sleepiness Scale (mean increase 0.09; 95% CI; −2.6, 2.8; <i>p</i> > 0.999), Beck Depression Inventory (BDI) (mean decrease −1.27; 95% CI; −3.8, 1.3; <i>p</i> = 0.257), and the Starkstein Apathy Scale (mean increase 0.36; 95% CI; −1.6, 2.4; <i>p</i> = 0.822). …"

Patient characteristics. حسب Stefan Halbherr (21353882)

"…No statistically significant improvements were seen in the Montreal Cognitive Assessment (MoCA) (mean decrease −0.73; 95% CI; −2.1, 0.62; <i>p</i> = 0.255), Epworth Sleepiness Scale (mean increase 0.09; 95% CI; −2.6, 2.8; <i>p</i> > 0.999), Beck Depression Inventory (BDI) (mean decrease −1.27; 95% CI; −3.8, 1.3; <i>p</i> = 0.257), and the Starkstein Apathy Scale (mean increase 0.36; 95% CI; −1.6, 2.4; <i>p</i> = 0.822). …"

Key safety measures including adverse events. حسب Anuja Dokras (8679261)

"…Waist circumference (mean change (MC) −2.23 cm; 95% CI [−3.98, −0.49]; <i>p</i> = 0.01), BMI (MC −0.49 kg/m²; 95% CI [−0.88, −0.10[; <i>p</i> = 0.01), and android fat mass measured by DXA (MC −167 g; 95% CI [−264, −71[; <i>p</i> < 0.001) decreased in the COCP group over the study period whilst there was no statistically significant changes in these parameters in the metformin only group when compared to baseline.. …"

Summary of correlations in previous studies. حسب Dan Kuang (136225)

"…Furthermore, the infection rates of SARS-CoV-2, as estimated by the model, ranged from 0.012% (P5-P95: 0.004% - 0.020%) at the lowest baseline to 3.27% (P5-P95: 1.23% - 5.69%) at the peak of the epidemic, with 15.1% (P5-P95: 5.65% - 26.2%) of individuals infected during the epidemic wave between March 4th and June 15th. Additionally, we did not observe any COVID-19 outbreaks or cluster infections at the Chengdu 2023 FISU World University Games village, and there was no significant difference in the concentrations of SARS-CoV-2 in athletes before and after check-in at the village.…"

The characteristics of nine WWTPs. حسب Dan Kuang (136225)

"…Furthermore, the infection rates of SARS-CoV-2, as estimated by the model, ranged from 0.012% (P5-P95: 0.004% - 0.020%) at the lowest baseline to 3.27% (P5-P95: 1.23% - 5.69%) at the peak of the epidemic, with 15.1% (P5-P95: 5.65% - 26.2%) of individuals infected during the epidemic wave between March 4th and June 15th. Additionally, we did not observe any COVID-19 outbreaks or cluster infections at the Chengdu 2023 FISU World University Games village, and there was no significant difference in the concentrations of SARS-CoV-2 in athletes before and after check-in at the village.…"

Clinical and Imaging Characteristics of Posterior Scleritis in Children حسب Ayala Katzir (20605679)

"…Retinal nerve fiber layer (RNFL) was thickened in all examined eyes (mean±SD 136.2 ± 28.4 µm) at presentation and it significantly decreased with treatment (109.8 ± 8.2 µm two months later). …"

Data Sheet 1_Exploring long COVID in pediatric patients: clinical insights from a long COVID clinic.docx حسب Dina Kamel (22434430)

"…Overall symptom burden decreased significantly over time (p < 0.001). Vaccination status at baseline was not associated with difference in symptom duration on initial presentation (p = 0.4). …"

Annual distribution of IG-ralated AE reports. حسب Shaozhi Liu (13720340)

"…We used Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Empirical Bayesian Geometric Mean (EBGM) for signal detection. …"

Proportion of AEs by SOCs in pregnant women. حسب Shaozhi Liu (13720340)

"…We used Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN), and Empirical Bayesian Geometric Mean (EBGM) for signal detection. …"

Dataset. حسب Nathan Mubiru (21627195)

"…Results were considered clinically significant if the percentage change was > 10% and if the p-value was < 0.05.…"

Table 2_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx حسب Chao-Chao Chen (21090215)

"…Understanding the potential connections among these metabolic diseases and the involvement of the brain in their progression presents an intriguing and critical area of research. In this study, we analyzed PET-CT images and clinical biomarkers from 112 cases of hypertension, 56 cases of T2DM, 11 cases of obesity, and 14 cases of gout. …"

Image 3_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff حسب Chao-Chao Chen (21090215)

"…Understanding the potential connections among these metabolic diseases and the involvement of the brain in their progression presents an intriguing and critical area of research. In this study, we analyzed PET-CT images and clinical biomarkers from 112 cases of hypertension, 56 cases of T2DM, 11 cases of obesity, and 14 cases of gout. …"

Table 1_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx حسب Chao-Chao Chen (21090215)

"…Understanding the potential connections among these metabolic diseases and the involvement of the brain in their progression presents an intriguing and critical area of research. In this study, we analyzed PET-CT images and clinical biomarkers from 112 cases of hypertension, 56 cases of T2DM, 11 cases of obesity, and 14 cases of gout. …"

Image 2_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff حسب Chao-Chao Chen (21090215)

"…Understanding the potential connections among these metabolic diseases and the involvement of the brain in their progression presents an intriguing and critical area of research. In this study, we analyzed PET-CT images and clinical biomarkers from 112 cases of hypertension, 56 cases of T2DM, 11 cases of obesity, and 14 cases of gout. …"

Table 3_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.xlsx حسب Chao-Chao Chen (21090215)

"…Understanding the potential connections among these metabolic diseases and the involvement of the brain in their progression presents an intriguing and critical area of research. In this study, we analyzed PET-CT images and clinical biomarkers from 112 cases of hypertension, 56 cases of T2DM, 11 cases of obesity, and 14 cases of gout. …"

Image 1_Relations between neurometabolism and clinical biomarkers in patients with metabolic disease.tiff حسب Chao-Chao Chen (21090215)

"…Understanding the potential connections among these metabolic diseases and the involvement of the brain in their progression presents an intriguing and critical area of research. In this study, we analyzed PET-CT images and clinical biomarkers from 112 cases of hypertension, 56 cases of T2DM, 11 cases of obesity, and 14 cases of gout. …"